Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs IQIYI Inc - ADR (IQ) Price & Performance

Ginkgo Bioworks Holdings IncTrade
IQIYI Inc - ADRTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs IQIYI Inc - ADR — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.04 (market cap $590.53M), while IQIYI Inc - ADR trades at $1.2 (market cap $1.12B). The key difference: IQIYI Inc - ADR is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.

DNAIQ
Market Cap
$590.53M$1.12B
Sector
HealthMedia
52-Week High
$16.14$2.79
52-Week Low
$5.48$0.96
Enterprise Value
$627.78M$2.69B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

IQIYI Inc - ADR

iQIYI (IQ) trades at $1.13 with no recent price movement, showing mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue decline of 13% year-over-year to $915.2M, missing expectations, though it beat EPS estimates. Valuation metrics show a high P/E ratio of 144.05 but attractive P/S of 0.29 and P/B of 0.57. Recent leadership changes and AI platform expansion highlight strategic shifts amid challenging fundamentals.

The outlook remains cautious with declining revenues and negative profitability margins creating headwinds. Analyst consensus leans bullish with 50% buy ratings, but execution risks and competitive pressures in China's streaming market pose significant challenges. The stock's current valuation disconnect between high P/E and low price-to-sales metrics suggests potential for recovery if AI initiatives drive growth, but near-term volatility is expected.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About IQIYI Inc - ADR

iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.

Read more on IQ